82-yr-old Guinea’s President, Conde, to run for 3rd term

Guineans return to the streets as anti-Conde protests resume — Guinea’s President Alpha Conde

Guinea’s ruling party on Monday confirmed months of speculation that President Alpha Conde will seek a third term in office, a possibility that had already sparked deadly mass protests.

The news came after the 82-year-old president pushed through a constitutional reform in March that critics had already argued was designed to allow him to run for office again in the October 18 election.

“President Alpha Conde will indeed be our candidate in the presidential election,” said the statement from the Rally of the Guinean People (RPG), read out on televsion.

ALSO READ: Guinea schedules presidential election for October 18

The party had formally nominated him to run again back in August, but Conde had made no formal response.

Under Guinea’s constitution, presidents may only serve two terms. Conde was elected president in 2010 and again in 2015.

But according to analysts, the new constitution could reset the presidential term counter and enable him to run a third time — a view now confirmed by the RPG.

[AFP]

Vanguard News Nigeria.

The post 82-yr-old Guinea’s President, Conde, to run for 3rd term appeared first on Vanguard News.

by Rasheed Sobowale via Vanguard News https://ift.tt/3hMPwRk Best Known Member of the Cabinet Wikipedia

Comments

Effective Data Governance: IIM-Africa inks partnership deal with Data Management University

President/Chairman of the governing council of IIM-Africa, Dr. Oyedokun Oyewole has said that effective data governance strategy has become more essential for the survival and sustenance of government and businesses, especially with the sudden outbreak of COVID-19 Pandemic. Oyewole said there is the need to ensure that the right policies, processes, technology, and people are in place to effectively manage data while complying with legal and regulatory requirements. He said that as part of the IIM Africa’s commitments towards ensuring global best practices, it has entered into a long-term partnership with DataManagementU.com to bring the finest data management training to industries across Africa. READ ALSO: COVID-19: Foreign affairs minister says first set of Nigerians abroad to be evacuated soon According to the IIM President, the alliance is expected to provide members of the Institute and other professionals across Africa, high standards, internationally-recognized learn...

Naomi Osaka’s statement about withdrawing from French Open

Japan’s Naomi Osaka returns the ball to Romania’s Patricia Maria Tig during their first round match of the French open tennis tournament at the Roland Garros stadium Sunday, May 30, 2021 in Paris. (AP Photo/Christophe Ena) Naomi Osaka tweeted the following statement announcing her withdrawal from the French Open on Monday: “Hey everyone, this isn’t a situation I ever imagined or intended when I posted a few days ago. I think now the best thing for the tournament, the other players and my well-being is that I withdraw so that everyone can get back to focusing on the tennis going on in Paris. ”I never wanted to be a distraction and I accept that my timing was not idea and my message could have been clearer. ”More importantly I would never trivialize mental health or use the term lightly. The truth is that I have suffered long bouts of depression since the US Open in 2018 and I have had a really hard time coping with that. Anyone that knows me knows I’m introverted, and anyone tha...

Remdesivir: The COVID-19 drug helping patients recover faster

A vial of the investigational drug remdesivir is visually inspected at a Gilead manufacturing site in the United States. PHOTO: AP Remdesivir has been shown to speed up recovery times for patients with COVID-19 in a major US-led trial, becoming the first drug with proven benefit against the disease. Here is what you need to know. – What is remdesivir? – Remdesivir is an experimental, broad spectrum antiviral made by US pharmaceutical Gilead Sciences that was first developed to treat Ebola, a viral hemorrhagic fever. It showed early promise in a primate study in 2016 and was later rolled out for a major trial in the Democratic Republic of Congo, where it was compared against three other medicines. That study concluded in 2019 when it was discontinued because it did not boost survival rates as greatly as two monoclonal antibody drugs, which are lab-engineered immune system proteins. In February, the US National Institute of Allergy and Infectious Diseases (NIAID) announced ...

Thorian

Search This Blog